CSIMarket
 
Senti Biosciences Inc   (SNTI)
Other Ticker:  
 
 
Price: $0.4005 $0.03 7.373%
Day's High: $0.47 Week Perf: 5.12 %
Day's Low: $ 0.36 30 Day Perf: -5.76 %
Volume (M): 95 52 Wk High: $ 1.38
Volume (M$): $ 38 52 Wk Avg: $0.65
Open: $0.38 52 Wk Low: $0.27



 Market Capitalization (Millions $) 18
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 60

Senti Biosciences Inc
Senti Biosciences Inc is a biotechnology company that specializes in developing synthetic biology platforms for advancing healthcare solutions. They focus on engineering cell and gene therapies to cure a variety of diseases by programming cells to detect and respond to specific signals within the body. Their innovative technology allows for precise control over cellular behaviors, enabling targeted therapies with enhanced safety and efficacy. Senti Biosciences Inc aims to revolutionize the field of medicine by harnessing the power of synthetic biology to create personalized treatments for patients.


   Company Address: 2 Corporate Drive, First Floor South San Francisco 94080 CA
   Company Phone Number: 239-2030   Stock Exchange / Ticker: NASDAQ SNTI
   SNTI is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Senti Bio Wins FDA Approval for SENTI-202 in Landmark Move to Treat Hematologic Cancer ?? Phase 1 Clinical Trial to Launch in 2024

Published Fri, Dec 22 2023 11:30 AM UTC

Senti Bio, the synthetic biology company pioneering the design and development of gene circuits, has recently received clearance for its Initial New Drug (IND) application from the Food and Drug Administration (FDA). The IND application is for SENTI-202, the company's investigational therapy designed to treat relapsed or refractory hematologic malignancies, including Acute M...

Senti Biosciences Inc

SNTI Stock Rebounds with Impressive Financial Performance in Q3 2023

The stock market is a dynamic and ever-changing industry. It is known for its ups and downs, and investors often look for positive news to give them confidence in their decisions. In the case of Senti Biosciences Inc, there is reason to be optimistic.
During the third quarter of 2023, SNTI, the stock of Senti Biosciences Inc, showed significant improvement in its financial performance. It decreased its loss per share to $-0.34, compared to $-0.38 in the previous year. Additionally, the company's earnings per share (EPS) improved from -$0.42 per share in the previous reporting season. These positive indicators demonstrate a step in the right direction for SNTI.

Senti Biosciences Inc

SNTI Reports Alarming $-0.42 Loss per Share in Q2 2023 as Declining Revenue Contributes to Financial Deterioration

As an analyst at Wall Street Journal, it is my duty to interpret and analyze the financial results of companies to provide valuable insights for our readers. Today, we will be taking a closer look at the financial results of Senti Biosciences Inc for the fiscal interval ending June 30, 2023.
SNTIs experienced a significant increase in loss per share during this period, rising from $-0.86 to $-0.42. This is certainly a cause for concern, especially when coupled with the decline in revenue by -31.001% to $0.94 million from $1.36 million a year ago. It is evident that declining business has played a significant role in the increase in losses.

Senti Biosciences Inc

Senti Biosciences Inc Reports Revenue of $1.286 Million in Q1 2023, While Showcasing an Improved ROA Ranking

Senti Biosciences Inc's financial results for the 12 months ending in the first quarter of 2023 show a cumulative net loss of $-77 million. This has resulted in a negative return on assets (ROA) of -41.76%, indicating that the company is not generating profits from its assets. In comparison, within the Healthcare sector, 551 other companies had a higher ROA.
Despite the low ROA, Senti Biosciences has seen an improvement in its overall ROA ranking, which has moved up from 4261 in the fourth quarter of 2022 to 3582 in the Mar 31 2023 quarter. This could be a positive sign for the company's future financial performance.






 

Senti Biosciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com